article · Burns Open
• Infection still causes high death and illness rates in burn patients. • Drug-resistant bacteria hinder treatment and extend hospital stays. • Surveillance and stewardship help prevent antibiotic resistance spread. Infections significantly contribute to mortality and morbidity in burn patients, with rising of antibiotic-resistant bacteria further complicates treatment, contributing to poor outcomes. This study determined the burden of infections in burn patients, including microbial etiology, drug resistance patterns, and patient outcomes, at a tertiary hospital in Tanzania. A retrospective cross-sectional study conducted from January 2021 to July 2022 recruited 158 burn patients (median age 3 years, IQR 1–20 years) at Muhimbili National Hospital. Data were obtained from medical records. Descriptive and logistic regression analysis ware performed using Statistical Package for the Social Sciences version 23.0, a p -value of <0.05 at 95% confidence intervals was significant. Of 158 burn patients, 117(74.1%) had infections; predominantly wound infection, 53.0% (n = 62). Wound and bloodstream infections were the predominant co-infections, 25.6% (n = 30), of which similar bacterial species were isolated in 33.3%(n = 10). Pseudomonas aeruginosa, was frequently isolated , found in 37.6%(n = 44) wounds and 50%(n = 2) urine samples. Staphylococcus aureus 33.3%(n = 18) and Coagulase-negative Staphylococci 29.6% (n = 16) w ere frequently isolated from blood. The isolated bacteria were resistant to most antibiotics; the proportion of multidrug-resistant strains was 61.5%(n = 72), 51.9%(n = 28), and 66.7%(n = 2) from wound, blood, and urine samples, respectively. Factors associated with mortality were multi-drug resistance infection (aOR:8.59, 95%CI:2.55–28.96, p = 0.001) and TSBA ≥21% (aOR:10.62, 95%CI:2.22–50.87, p = 0.003). The Majority of burn patients develop infection with multidrug-resistant strains. Mortality was significantly associated with multi-drug resistance and TSBA ≥21%. Therefore, regular surveillance and strengthened stewardship are essential to guide treatment and curb antibiotic resistance.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1016/j.burnso.2026.100453
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
